Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

NCT03214666 is registered in ClinicalTrials.gov with GT Biopharma, Inc. as lead sponsor.

NCT NCT03214666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03214666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Lead sponsor
GT Biopharma, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 1, 2020
Completion date
September 29, 2021
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, high-risk myelodysplastic syndromes, mast cell leukemia, systemic mastocytosis